<DOC>
	<DOCNO>NCT00701103</DOCNO>
	<brief_summary>This study look high tolerate dose dalotuzumab ( MK-0646 ) give weekly , every week . every three week infusion . The hypothesis study administration dalotuzumab one- two-hour weekly , every week , every three week infusion participant advance cancer generally safe tolerate dose achieves trough concentration ≥3 μg/mL .</brief_summary>
	<brief_title>Dose Escalation Trial Dalotuzumab ( MK-0646 ) Advanced Solid Tumors Multiple Myeloma ( MK-0646-001 )</brief_title>
	<detailed_description>Trial Duration Treatment : Participants treat two year disease progress unmanageable side effect .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participant metastatic locally advanced solid tumor multiple myeloma Tumor specimen IGF1R expression Participant agree use birth control throughout study Participant must recover antineoplastic therapy last 4 week Participant participate clinical trial last 4 week Participant history heart problem congestive heart failure , angina , heart attack stroke last 3 month Participant take growth hormone growth hormone inhibitor If female , participant pregnant breastfeeding Participant human immunodeficiency virus ( HIV ) positive Participant history hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>